SCHEMBL3016285

SCHEMBL3016285

COc1ccc(Cl)cc1S(=O)(=O)C1CCN(c2nc(Cc3cc(C)cc(C)c3)cs2)CC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.39
MAPT P10636 3/20 0.39
TP53 P04637 2/20 0.39
HTT P42858 1/20 0.39
ALDH1A1 P00352 2/20 0.38
HPGD P15428 2/20 0.38
KDM4E B2RXH2 1/20 0.38
POLB P06746 1/20 0.38
RAB9A P51151 1/20 0.38
CPT1A P50416 5/20 0.37
DRD2 P14416 2/20 0.36
ADRA1D P25100 2/20 0.36
ADRA1A P35348 2/20 0.36
ADRA1B P35368 2/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2C19 P33261 1/20 0.36
CPT1B Q92523 4/20 0.36
TSHR P16473 2/20 0.36
KMT2A Q03164 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3006331 0.94 TP53 (0.40) MAPK1MAPTTP53HTTALDH1A1
SCHEMBL3014929 0.93 MAPK1 (0.39) MAPK1MAPTTP53HTTALDH1A1
SCHEMBL3022242 0.93 MAPK1 (0.38) MAPK1MAPTTP53HTTALDH1A1
SCHEMBL3018474 0.92 MAPT (0.40) MAPK1MAPTTP53HTTALDH1A1
SCHEMBL3013284 0.91 CYP3A4 (0.39) MAPK1MAPTTP53HTTALDH1A1
SCHEMBL3013816 0.91 TP53 (0.38) MAPK1MAPTTP53HTTALDH1A1
SCHEMBL3007436 0.91 MAPK1 (0.39) MAPK1MAPTTP53HTTALDH1A1
SCHEMBL15671702 0.91 MAPT (0.42) MAPK1MAPTTP53HTTALDH1A1
SCHEMBL3007108 0.90 TDP1 (0.42) MAPK1MAPTTP53HTTALDH1A1
SCHEMBL3010626 0.90 ALDH1A1 (0.45) MAPTALDH1A1HPGDPOLBRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPK1 2767/4885MAPT 18/4885TP53 2880/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.